U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 29 results

Status:
US Approved Rx (2015)
First approved in 2012

Class (Stereo):
CHEMICAL (ABSOLUTE)



Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor used in combination with cobicistat, emtricitabine and tenofovir alafenamid (GENVOYA®) for the treatment of HIV-1 infection in antiretroviral treatment-...
Status:
US Approved Rx (2022)
First approved in 2008

Class (Stereo):
CHEMICAL (ACHIRAL)



Etravirine (formerly known as TMC125) is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immuno...
Status:
US Approved Rx (2008)
First approved in 2005

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tipranavir (PNU-140690, trade mark APTIVUS) is a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Tipranavir has potent in vitro activity against a variety of HIV-1 laboratory str...
Status:
US Approved Rx (2018)
First approved in 2003

Class (Stereo):
CHEMICAL (ABSOLUTE)



Emtricitabine was discovered by Emory researchers Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi and Dr. Woo-Baeg Choi and licensed to Triangle Pharmaceuticals by Emory University in 1996. Triangle was acquired by Gilead in 2003. Emtricitabine, market...
Status:
US Approved Rx (2016)
First approved in 1999

Class (Stereo):
CHEMICAL (ABSOLUTE)



Amprenavir is an inhibitor of HIV-1 protease. Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature non-infectious viral parti...
Status:
US Approved Rx (2013)
First approved in 1998

Class (Stereo):
CHEMICAL (ABSOLUTE)



Abacavir is a nucleoside reverse transcriptase inhibitor used for treatment of HIV infection (either alone or in combination with other antiviral drugs). It was shown that abacavir exerts its antiviral activity through its active metabolite, carbovir...
Status:
US Approved Rx (2020)
First approved in 1998

Class (Stereo):
CHEMICAL (ABSOLUTE)



Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV in...
Status:
US Previously Marketed
First approved in 1996

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...
Status:
US Previously Marketed
First approved in 1995

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Saquinavir (brand names Invirase and Fortovase) is an antiretroviral drug used together with other medications to treat or prevent HIV/AIDS. Saquinavir is an inhibitor of HIV protease. HIV protease is an enzyme required for the proteolytic cleavage o...
Status:
US Previously Marketed
First approved in 1992

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

The nucleoside analog 2',3'-dideoxycytidine (ddCyd), also known as Zalcitabine is a nucleoside analog reverse transcriptase inhibitor (NRTI) sold under the trade name Hivid. HIVID is indicated in combination with antiretroviral agents for the treatme...